23:43 , Nov 12, 2018 |  BC Extra  |  Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) on Monday proposed to list on the Hong Kong...
21:20 , Nov 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer; cancer...
19:31 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Priority Review for Dupixent in adolescent atopic dermatitis

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA accepted and granted Priority Review to an sBLA for Dupixent dupilumab to treat adolescents ages 12 to 17 with moderate to severe atopic dermatitis whose...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
20:04 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

MyoKardia's heart failure candidate shows proof of mechanism in Phase Ia

MyoKardia Inc. (NASDAQ:MYOK) reported data from a Phase Ia trial in healthy volunteers showing that heart failure candidate MYK-491 increased cardiac contractility by 5-20% across multiple echocardiographic parameters with minimal effect on diastolic function. The...
20:02 , Nov 2, 2018 |  BC Week In Review  |  Company News

Sanofi deal will bank roll Denali's indication expansion

Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most...
19:58 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Sanofi gets Priority Review for dengue vaccine

Sanofi (Euronext:SAN; NYSE:SNY) said FDA accepted and granted Priority Review to a BLA for Dengvaxia dengue tetravalent vaccine. The PDUFA date is May 1, 2019. If approved, Dengvaxia "would represent the first and only medical...
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Schrödinger, WuXi AppTec launch drug discovery JV

Computational physics company Schrödinger LLC (New York, N.Y.) and Shanghai-based R&D company WuXi AppTec Co. Ltd. (Shanghai:603259) created drug discovery JV Faxian Therapeutics (New York, N.Y.). The JV will use Schrödinger's precision molecular design platforms...
15:33 , Nov 1, 2018 |  BC Extra  |  Company News

Sanofi deal will bank roll Denali's indication expansion

Sanofi (Euronext:SAN; NYSE:SNY) paid Denali Therapeutics Inc. (NASDAQ:DNLI) $125 million in cash up front to co-develop multiple receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1) inhibitors to treat neurological and systemic inflammatory diseases. Sanofi will cover most...
22:55 , Oct 30, 2018 |  BC Extra  |  Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...